Net Debt Summary of Chromocell Therapeutics Corporation

Chromocell Therapeutics Corporation's latest annual net debt in 2023 was 1.17 Million USD , up 141.53% from previous year.
Chromocell Therapeutics Corporation's latest quarterly net debt in 2024 Q2 was -817.81 Thousand USD , up 78.31% from previous quarter.
Chromocell Therapeutics Corporation reported annual net debt of 485.35 Thousand USD in 2022, down -55.87% from previous year.
Chromocell Therapeutics Corporation reported annual net debt of 1.09 Million USD in 2021, up 354.91% from previous year.
Chromocell Therapeutics Corporation reported quarterly net debt of -817.81 Thousand USD for 2024 Q2, up 78.31% from previous quarter.
Chromocell Therapeutics Corporation reported quarterly net debt of 1.17 Million USD for 2023 FY, up 141.53% from previous quarter.

Annual Net Debt Chart of Chromocell Therapeutics Corporation (2023 - 2020)

Name	Net Debt	Net Debt Difference
AIM ImmunoTech Inc.	-4.94 Million USD	123.711%
Ampio Pharmaceuticals, Inc.	-3.81 Million USD	130.729%
Armata Pharmaceuticals, Inc.	106.84 Million USD	98.903%
Actinium Pharmaceuticals, Inc.	-74.56 Million USD	101.572%
Azitra, Inc.	-910.04 Thousand USD	228.818%
Can-Fite BioPharma Ltd.	-4.23 Million USD	127.661%
Calidi Biotherapeutics, Inc.	5.18 Million USD	77.399%
CEL-SCI Corporation	9.42 Million USD	87.563%
iBio, Inc.	-9.75 Million USD	112.024%
Lineage Cell Therapeutics, Inc.	-32.49 Million USD	103.608%
MAIA Biotechnology, Inc.	-7.15 Million USD	116.394%
Matinas BioPharma Holdings, Inc.	-1.28 Million USD	191.514%
Navidea Biopharmaceuticals, Inc.	438.44 Thousand USD	-167.376%
NovaBay Pharmaceuticals, Inc.	-390 Thousand USD	400.588%
NanoViricides, Inc.	-4.79 Million USD	124.434%
Oragenics, Inc.	-3.17 Million USD	136.972%
BiomX Inc.	-772 Thousand USD	251.852%
BiomX Inc.	-772 Thousand USD	251.852%
Protalix BioTherapeutics, Inc.	2.64 Million USD	55.712%
Palatin Technologies, Inc.	-8.93 Million USD	113.117%
Scorpius Holdings, Inc.	13.85 Million USD	91.54%